Highlights:

  • The United States FDA has accepted Telix Pharmaceuticals' resubmitted New Drug Application (NDA) for TLX101-Px (Pixclara®, Floretyrosine F 18 or 18F-FET), a PET imaging agent for characterising recurrent or progressive glioma, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of September 11, 2026 — the target date by which the FDA aims to complete its review.
  • TLX101-Px (Pixclara®) holds both Fast Track and Orphan Drug designations from the FDA, reflecting the product's potential to address a critical unmet medical need in glioma imaging that currently lacks US-approved options, despite 18F-FET neuroimaging being broadly recommended in international clinical practice guidelines including the NCCN Guidelines® for Central Nervous System Cancers.
  • If approved, Pixclara® would be the first US-approved 18F-FET PET imaging agent for glioma, with an estimated 24,000 new glioma cases diagnosed annually in the US and recurrence occurring in almost all glioblastoma patients following standard treatment — creating a substantial addressable patient population for repeat imaging assessments.

Telix Pharmaceuticals Limited (ASX:TLX) (NASDAQ:TLX) shares advanced 3.885% to $14.170 on April 10, 2026, with 1,048,449 shares traded and a market capitalisation of $4.62 billion, after the company announced that the United States Food and Drug Administration has accepted its resubmitted New Drug Application for TLX101-Px, commercially branded as Pixclara®. The FDA has assigned a PDUFA goal date of September 11, 2026 — the formal target date by which the agency aims to complete its review and issue a regulatory decision. The acceptance of the NDA resubmission is a meaningful regulatory milestone that confirms the FDA has reviewed the submission for completeness and determined that it is sufficiently complete to permit a substantive review, advancing Pixclara® into the formal pre-approval regulatory review process.

TLX101-Px (Pixclara®): The Product and the Unmet Need

TLX101-Px, commercially branded as Pixclara® (subject to final regulatory approval), is a PET (positron emission tomography) imaging agent based on Floretyrosine F 18 (18F-FET). The product is designed for the imaging of glioma — brain cancers arising from glial cells — and specifically for the characterisation of recurrent or progressive glioma in distinction from treatment-related changes. This distinction is clinically critical: a common challenge in the management of glioma patients who have undergone treatment with radiotherapy and chemotherapy is that imaging changes on conventional MRI may reflect either true tumour recurrence or pseudo-progression — a treatment-related inflammatory response that can mimic tumour growth on standard imaging. The inability to reliably distinguish these two outcomes has significant consequences for clinical decision-making, as true recurrence may require salvage treatment while pseudo-progression typically resolves without intervention.

18F-FET PET imaging addresses this diagnostic challenge through a different biological mechanism than conventional MRI. 18F-FET is an amino acid analogue that is preferentially taken up by tumour cells through L-type amino acid transporters (LAT1 and LAT2), which are upregulated in active tumour tissue. By imaging the spatial distribution of this metabolic activity, 18F-FET PET can identify areas of active tumour growth that may not be distinguishable from treatment effect on conventional MRI. This capability is already broadly endorsed in international clinical practice guidelines — including joint guidelines from the European Association of Nuclear Medicine, European Association of Neuro-Oncology, and other major societies, as well as the NCCN Guidelines® for Central Nervous System Cancers — but currently lacks an FDA-approved product available to US patients and clinicians.

Thomas Hope, MD, Vice Chair at UCSF, articulated the clinical need: "There remains a critical unmet need in improving our ability to image residual glioma after treatment." Patrick Wen, MD, at Mass General Brigham Cancer Institute added that distinguishing tumour progression from treatment-related change "remains one of the most challenging aspects of glioma care," and described 18F-FET PET as "an important tool in clinical practice worldwide." These endorsements from leading academic neuro-oncology centres confirm both the clinical validity of the diagnostic approach and the unmet need that Pixclara® is positioned to address in the US market.

The NDA Resubmission: Why the FDA Accepted the Application

The resubmitted NDA was submitted on 13 March 2026 following an earlier submission that required resubmission — a process that occurs when the FDA identifies deficiencies in an initial submission that prevent a complete review. The fact that the FDA has now accepted the resubmission indicates that the agency has reviewed the resubmitted package for completeness and determined that it contains sufficient information to permit a substantive evaluation. Acceptance is a procedural hurdle, not a regulatory approval, but it is a necessary prerequisite to the formal review process and the assignment of a PDUFA date.

The PDUFA goal date of September 11, 2026 represents the target completion date under the Prescription Drug User Fee Act framework, which establishes performance goals for FDA review timelines in exchange for industry user fee payments that fund the review process. PDUFA dates are aspirational targets rather than binding legal deadlines, but the FDA's historical performance in meeting PDUFA goals for standard review applications has been consistent, making the September 11 date a meaningful indicator of the expected regulatory decision timeline.

Telix CEO of Precision Medicine Kevin Richardson described the FDA's acceptance as "an important milestone" and noted the company's intention to "work closely with the Agency to urgently obtain approval and then bring this product to market for the benefit of patients." The characterisation of the desired path as urgent reflects both the clinical need and the commercial priority that Pixclara® represents for the company's US precision medicine business.

Regulatory Designations: Fast Track and Orphan Drug

TLX101-Px carries both Fast Track and Orphan Drug designations from the FDA — two regulatory mechanisms that acknowledge the product's potential to address serious conditions with unmet medical needs. Fast Track designation is designed to facilitate the development and expedite the review of drugs for serious conditions, with benefits including more frequent FDA interactions during development and eligibility for rolling review — a process by which the FDA can review completed sections of the application prior to the final full submission. The prior Fast Track designation (granted April 2024) has supported the development program and the agency interactions that informed the resubmitted NDA.

Orphan Drug designation (granted October 2020) acknowledges that glioma qualifies as a rare disease under FDA criteria — reflecting the approximately 24,000 new glioma cases diagnosed annually in the US. Orphan Drug designation provides the sponsor with a seven-year period of market exclusivity upon approval, tax credits for clinical testing costs, and fee waivers for certain FDA applications. The market exclusivity period, in particular, is commercially important as it creates a window of protected market position for Pixclara® following any US approval.

The Glioma Market: Incidence, Recurrence and Imaging Demand

Gliomas are the most common form of central nervous system cancer originating from glial cells, accounting for approximately 30% of all brain and CNS tumours and 80% of all malignant brain tumours. In the US, there are approximately 24,000 new glioma cases diagnosed annually. Glioblastoma (GBM), the most common and aggressive form, has an expected survival duration of 12-15 months from diagnosis despite the standard of care treatment comprising surgical resection followed by combined radiotherapy and chemotherapy. Recurrence occurs in almost all GBM patients, creating a large and recurring demand for post-treatment imaging assessments.

The recurring nature of glioma and the multiple imaging assessments required across the treatment and monitoring continuum creates a substantial annual volume of imaging procedures per patient. A diagnostic imaging agent that enables more reliable characterisation of post-treatment scans would be used not once but repeatedly across the course of each patient's disease management, creating a sustained demand profile for Pixclara® per patient that is distinct from single-use therapeutic products.

Connection to TLX101-Tx Therapy: A Diagnostic-Therapeutic Pair

TLX101-Px's targeting of LAT1 and LAT2 transporters creates a strategic linkage with Telix's TLX101-Tx therapy candidate (iodofalan 131I), which is currently under investigation in the pivotal IPAX-BrIGHT trial in patients with recurrent glioblastoma. As a LAT1-targeting therapy, TLX101-Tx may be most effective in patients whose tumours express LAT1 at high levels — and TLX101-Px, by imaging LAT1 expression via 18F-FET uptake, has the potential to be used as a patient selection tool and response assessment tool for TLX101-Tx treatment. This diagnostic-therapeutic pair concept creates a vertically integrated precision medicine model where Telix can potentially manage patient selection, treatment administration, and response monitoring within its own product portfolio.

Financial Guidance and Commercial Contribution

Telix confirmed that its FY2026 financial guidance does not include any revenue contribution from TLX101-Px. This disclosure is important context for investors: the September 11 PDUFA date, if met and resulting in approval, would generate US commercial revenue only in the period following product launch — likely late 2026 at the earliest following FDA approval, manufacturing and distribution preparation, and commercial launch activities. Any material revenue from Pixclara® would therefore be a FY2027 and beyond contributor rather than a FY2026 driver.

Conclusion

Telix Pharmaceuticals' 3.885% advance to $14.170 on April 10, 2026 — with market capitalisation of $4.62 billion — reflected the market's recognition of the FDA NDA acceptance as a meaningful progression in the regulatory pathway for Pixclara®. The PDUFA goal date of September 11, 2026 establishes a clear timeline for the FDA's review decision, with Fast Track and Orphan Drug designations providing regulatory process advantages and a seven-year exclusivity period on approval. The clinical unmet need is well-documented — 24,000 annual US glioma diagnoses, near-universal GBM recurrence, and the absence of an FDA-approved 18F-FET PET agent despite broad international guideline endorsement — creating the conditions for rapid clinical adoption if approval is granted. The diagnostic-therapeutic pairing potential with TLX101-Tx provides an additional strategic dimension that positions Pixclara® as more than a standalone product. Revenue from TLX101-Px is excluded from FY2026 guidance, meaning any commercial contribution from approval would represent guidance-exceeding upside for FY2026 and a material FY2027 addition to Telix's revenue base.